Coeptis Therapeutics Holdings, Inc. (COEPW)

USD 0.03

(28.5%)

Market Cap (In USD)

8.67 Million

Revenue (In USD)

-

Net Income (In USD)

-21.26 Million

Avg. Volume

-

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.0196-0.0259
PE
-
EPS
-
Beta Value
-0.58957
ISIN
US19207A1161
CUSIP
19207A116
CIK
1759186
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. David Mehalick
Employee Count
-
Website
https://coeptispharma.com
Ipo Date
Details
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.